Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy

NCT01297101 · clinicaltrials.gov ↗

TEMPORARILY_NOT_AVAILABLE

Status

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Erlotinib

Sponsor

Shanghai Chest Hospital

Collaborators

[object Object]
[object Object]